<DOC>
	<DOC>NCT02616185</DOC>
	<brief_summary>The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histological or cytological diagnosis of prostate cancer Adequate bone marrow, kidney and liver function Hormone sensitive relapsing prostate cancer after definitive local therapy (biochemical relapse) OR Progressive disease postsurgical castration or during androgen suppression therapy (presecondary hormone CRPC) OR Failed prior therapy with a secondary hormone (e.g. enzalutamide, abiraterone) with documented progressive disease (postsecondary hormone CRPC) Cancerrelated pain requiring scheduled opioid narcotics for control ECOG performance status greater than or equal to 2 Concurrent immunotherapy for prostate cancer History of or active autoimmune disorders or history of inflammatory bowel disorders Current use of any implanted electronic stimulation device For biochemically relapsed patients, no concurrent use of ADT or orchiectomy and no known prior or current evidence of any metastatic involvement of distant organs For presecondary hormone patients, no prior or concurrent treatment with a secondary hormone (e.g. enzalutamide, abiraterone) and no metastasis to organ systems other than lymph nodes and/or bone For postsecondary hormone patients, no concurrent treatment with a secondary hormone (e.g. enzalutamide, abiraterone), no metastasis to the liver or brain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>